- Medtronic is scheduled to report Q1 results after the September 1 market close; consensus calls for EPS of $1.39, up 10.3% year over year, and revenue growth of 12.2%.
- The FDA's August 27 early alert covers specified Bravo CF capsule delivery devices after Medtronic instructed customers to quarantine and return affected products; 184 serious injuries had been reported as of August 10, with no deaths.
- Needham expects Medtronic to beat Q1 revenue and EPS estimates, raise FY27 guidance, and deliver organic growth of at least 6% in FY27, citing product launches and market expansion.
Quotes
“The consensus EPS Estimate is $1.39, which translates to a 10.3% Y/Y rise, while revenue is seen improving by +12.2% Y/Y”
“raised its price target to $114 from $101.”